mg冰球突破豪华版试玩网站

Jiangsu Recbio Technology Co., Ltd. is pleased to announce that the Company has entered into a product licensing cooperation agreement with the renowned Indian biopharmaceutical company Biological E recently regarding the recombinant HPV 9-valent vaccine REC603. The Company will license the vaccine formulation, filling and packaging technologies to BE Company, and further license the drug substance production technology at an appropriate time. Pursuant to the Agreement, BE Company is granted an exclusive license to develop, manufacture, and commercialize the recombinant HPV 9-valent vaccine in India and in the tender markets led by the United Nations International Children’s Emergency Fund (UNICEF) and the Pan American Health Organization (PAHO). At present, the Company has received the upfront payment for this cooperation and will receive milestone payments based on the progress of the cooperation, as well as royalties calculated at a certain percentage of the annual net sales.

It is reported that India has a population of approximately 1.44 billion, with about 23 million newborns each year, demonstrating enormous market potential for HPV vaccines. Founded in 1953, BE Company is India’s first private biopharmaceutical enterprise, boasting rich experience in vaccine R&D, manufacturing, and commercialization, and serving as an important partner of UNICEF and PAHO. This strategic cooperation with BE Company marks another significant milestone for the Company in actively expanding into the Indian and broader international markets.

Headquartered in Hyderabad, India, BE Company is a pharmaceutical and biopharmaceutical enterprise. BE Company is dedicated to the development, production, and supply of vaccines and therapeutic drugs. Its vaccine products are supplied to more than 140 countries globally, while its therapeutic products are marketed in the Indian, US, and European markets. At present, BE Company’s product portfolio includes 10 vaccines approved by the World Health Organization (WHO) and 10 generic injectables approved by the US Food and Drug Administration (USFDA).

Cervical cancer ranks as the fourth leading cause of cancer-related deaths among women worldwide. The HPV 9-valent vaccine can prevent approximately 90% of cervical cancer, anal cancer, and genital warts, making it the most effective HPV vaccine currently available in the market. As the core product of the Company, the recombinant HPV 9-valent vaccine REC603 is indicated for individuals aged 9 to 45 and is currently in the critical follow-up phase of Phase III clinical trials in China.

About Recbio

Founded in 2012, Jiangsu Recbio Technology Co., Ltd. (hereafter referred to as Recbio or the Company; stock code: 2179.HK) is an innovative vaccine company propelled by internally developed technologies. Committed to our mission of " Protect human health with best-in-class vaccines", we have cultivated a robust portfolio of vaccine products with exclusive rights, addressing the substantial unmet needs in the realm of high-impact infectious diseases. Over the course of more than two decades, Recbio has meticulously built three pioneering platforms: a novel adjuvant platform, a protein engineering platform, and an immunological evaluation platform, making us one of the few global companies capable of both developing and manufacturing the complete range of novel adjuvants.
Leveraging the close integration of our three platforms, we are consistently creating promising vaccine candidates. Fueled by these innovative platforms, the Company has forged a high-value portfolio of innovative vaccines, encompassing over ten potential blockbuster varieties. These encompass areas such as cervical cancer, shingles, RSV infection, and other prevalent high-burden diseases, and have emerged as leading products in terms of development and clinical progress in China.
Having been honed and refined over the course of a decade, Recbio is poised to reap the benefits as several products are nearing commercialization.

Forward-looking statements

This Press Release may contain projections, estimates, forecasts, targets, opinions, prospects, results, returns and forward-looking statements with respect to the financial condition, results of operations, capital position, strategy and business of the Group which can be identified by the use of forward-looking terminology such as “may”, “will”, “should”, “expect”, “anticipate”, “project”, “plan”, “estimate”, “seek”, “intend”, “target”, “believe”, “potential” and “reasonably possible” or the negatives thereof or other variations thereon or comparable terminology (collectively, “forward-looking statements”), including the strategic priorities, research and development projects, and any financial, investment and capital targets and any other targets, commitments and ambitions described in writing or verbally herein. Any such forward-looking statements are not a reliable indicator of future performance, as they may involve significant stated or implied assumptions and subjective judgements which may or may not prove to be correct, accurate or complete. There can be no assurance that any of the matters set out in the forward-looking statements are attainable, will actually occur or will be realised or are complete or accurate. The assumptions and judgments may prove to be incorrect, inaccurate or incomplete, and involve known and unknown risks, uncertainties, contingencies and other important actors, many of which are outside the control of the Group. There is also no assurance that the Group may develop or market its core products or other pipeline candidates successfully. Actual achievements, results, performance or other future events or conditions may differ materially from those stated, implied and/or reflected in any forward-looking statements due to a variety of risks, uncertainties and other factors (including without limitation general market conditions, regulatory changes, geopolitical tensions or data limitations and changes). Any such forward-looking statements are based on the beliefs, expectations and opinions of the Group at the date the statements are made, and the Group does not assume, and hereby disclaims, any obligation or duty to update, revise or supplement them if circumstances or management’s beliefs, expectations or opinions should change. For these reasons, you should not place reliance on, and are expressly cautioned about relying on, any forward-looking statements. No representations or warranties, expressed or implied, are given by or on behalf of the Group as to the achievement or reasonableness of any projections, estimates, forecasts, targets, commitments, prospects or returns contained herein.
Please refer to the announcements published by the Company on the websites of The Stock Exchange of Hong Kong Limited (www.hkexnew.hk) or of the Company (www.recbio.cn) for further details. If there is any inconsistency between this Presentation and the announcements, the announcements shall prevail.